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Abstract
Background. Lanthanum carbonate (FOSRENOL
®, Shire
Pharmaceuticals) is an effective non-calcium, non-resin
phosphate binder for the treatment of hyperphosphataemia
inpatientswithchronickidneydisease(CKD).Inthisstudy,
we used a rat model of chronic renal failure (CRF) to exam-
ine the long-term effects of controlling serum phosphorus
with lanthanum carbonate treatment on the biochemical
and bone abnormalities associated with CKD–mineral and
bone disorder (CKD–MBD).
Methods. Rats were fed a normal diet (normal renal func-
tion, NRF), or a diet containing 0.75% adenine for 3 weeks
to induce CRF. NRF rats continued to receive normal diet
plus vehicle or normal diet supplemented with 2% (w/w)
lanthanum carbonate for 22 weeks. CRF rats received a
diet containing 0.1% adenine, with or without 2% (w/w)
lanthanum carbonate. Blood and urine biochemistry were
assessed, and bone histomorphometry was performed at
study completion.
Results. Treatment with 0.75% adenine induced severe
CRF, as demonstrated by elevated serum creatinine. Hyper-
phosphataemia, hypocalcaemia, elevated calcium × phos-
phorus product and secondary hyperparathyroidism were
evident in CRF + vehicle animals. Treatment with lantha-
num carbonate reduced hyperphosphataemia and second-
ary hyperparathyroidism in CRF animals (P < 0.05), and
had little effect in NRF animals. Bone histomorphometry
revealed a severe form of bone disease with fibrosis in
CRF + vehicle animals; lanthanum carbonate treatment
reduced the severity of the bone abnormalities observed,
particularly woven bone formation and fibrosis.
Conclusions. Long-term treatment with lanthanum car-
bonate reduced the biochemical and bone abnormalities
of CKD–MBD in a rat model of CRF.
Keywords: bone disease; chronic kidney disease–mineral and bone
disorder; FOSRENOL; lanthanum carbonate; phosphate binder
Introduction
Chronic kidney disease (CKD) affects ~17% of the adult
population in the USA [1]. For these patients, death is a
more likely outcome than progression to dialysis, primarily
because of cardiovascular disease [2]. CKD–mineral and
bone disorder (CKD–MBD) describes a triad of inter-
related biochemical, bone and vascular abnormalities that
have been linked with increased cardiovascular-related
morbidity and mortality in patients with CKD [3].
Disturbed phosphorus homeostasis is central to the
pathophysiology of CKD–MBD. Excretion of phosphorus
declines as CKD progresses, resulting in a positive phos-
phorus balance and the eventual development of hyperpho-
sphataemia. This state is linked to an increased mortality
risk in patients with CKD [4]. A key role of phosphorus is
to stimulate synthesis and secretion of parathyroid hor-
mone (PTH) and parathyroid cell proliferation [5–7].
These effects occur both directly via post-transcriptional
processes [8], and indirectly through inhibition of 1,25-
dihydroxyvitamin D metabolism and via skeletal resistance
to the actions of PTH [9].
Secondary hyperparathyroidism and parathyroid gland
hyperplasia often develop early during the course of
CKD; the latter (nodular hyperplasia) is often irreversible
and may be refractory to therapy. Ultimately, these abnor-
malities lead to a high-turnover form of renal bone disease.
Therefore, it is important to prevent parathyroid gland
hyperplasia and secondary hyperparathyroidism by con-
trolling the biochemical abnormalities of CKD–MBD, in-
cluding elevated phosphorus levels, early in the course of
disease [10].
The non-calcium, non-resin phosphate binder lan-
thanum carbonate (FOSRENOL
®, Shire Pharmaceuticals,
Basingstoke, UK) is commonly used in clinical practice to
reduce serum phosphorus in patients with CKD stage 5
who are undergoing dialysis. Sustained reduction of serum
phosphorus has been demonstrated in clinical trials [11];
© The Author 2010. Published by Oxford University Press on behalf of the ERA-EDTA. All rights reserved. This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and
reproduction in any medium, provided the original work is properly cited.further studies have also suggested improvement in bone
parameters in some patients [12–14].
In rats, severe hyperparathyroidism occurs when chronic
renal failure (CRF) is chemically induced by addition of
adenine to the diet [15,16]. Short-term dietary supplemen-
tation of adenine has been used to examine the effects of
phosphate binders in studies of up to 12 weeks in duration
[17,18]. Adenine is metabolized to 2,8-dihydroxyadenine,
which precipitates as crystals in the microvilli and apical
region of the proximal tubular epithelia, thus inducing se-
vere CRF [19]. The resulting CRF is characterized by in-
creased levels of serum creatinine and phosphorus, and
decreased levels of serum calcium [15]. This model pro-
vides a rapid and reliable method of inducing severe sec-
ondary hyperparathyroidism with rapid deterioration of
bone within 4 weeks, and is considered to be compatible
with clinical observations in dialysis patients [16].
The objective of this study was to evaluate the long-term
effect of controlling serum phosphorus with lanthanum
carbonate on biochemical and bone parameters in a rat
model (adenine-induced) of severe secondary hyperpara-
thyroidism. We also examined the effects of long-term
treatment with lanthanum carbonate on tissue lanthanum
deposition and liver function.
Materials and methods
Animals and diets
Male Wistar rats (Hsd:WI) were obtained from Harlan Sprague Dawley,
Inc. (Indianapolis, IN, USA). At the start of the study, rats were 12 weeks
old and weighed ~250–275 g; body weight was measured weekly
throughout the study. Rats were housed one per polycarbonate cage with
a 12-h light–dark cycle and were given free access towater. During 1 week
of acclimatization, animals were fed Teklad standard diet containing 0.8%
calcium, 0.6% phosphorus, 21% protein and 2 IU/g vitamin D. Subse-
quent experimental diets are described below. The study protocol was ap-
proved by the Institution of Animal Care and Use Committee at MDS
Pharma Services (Bothell, WA, USA).
Induction and maintenance of chronic renal failure
Animals were randomized into treatment groups based on body weight.
CRF was induced by feeding rats an adenine-supplemented diet [0.75%
Fig. 2. Changes in (A) serum phosphorus, (B) ionized calcium and (C)
calcium × phosphorus product in rats with normal renal function or
chronic renal failure during 22 weeks of treatment with vehicle or
lanthanum carbonate. A. *P = not significant, CRF + lanthanum
carbonate vs NRF groups.
†P < 0.05 vs all other groups. B. *P = not
significant, CRF + lanthanum carbonate vs NRF groups. P < 0.05,
CRF + lanthanum carbonate vs CRF + vehicle, Week 0–22. C.
*P = not significant, CRF + lanthanum carbonate vs NRF groups.
P < 0.05, CRF + lanthanum carbonate vs CRF + vehicle, Week 4–22.
Calcium × phosphorus product was calculated using total calcium. Data
are presented as mean ± standard error of the mean. NRF, normal renal
function; CRF, chronic renal failure. Dashed vertical line indicates
initiation of vehicle or lanthanum carbonate treatment.
Fig. 1. Changes in serum creatinine in rats with normal renal function or
chronic renal failure during 22 weeks of treatment with vehicle or
lanthanum carbonate. *P < 0.05 vs all other groups. Data are presented
as mean ± standard error of the mean. NRF, normal renal function; CRF,
chronic renal failure. Dashed vertical line indicates initiation of vehicle or
lanthanum carbonate treatment.
1804 S. Damment et al.(w/w) adenine] for 3 weeks according to the protocol described by Yoko-
zawa et al. [15]. Control rats with normal renal function (NRF) were fed a
similar diet excluding adenine.
After the initial 3-week disease-induction period, rats were divided into
four different treatment groups (n = 10 per group). NRF animals were fed
a normal diet supplemented with 2% cellulose as vehicle or a diet supple-
mented with 2% (w/w) lanthanum carbonate (1% w/w elemental lan-
thanum, supplied by DHP Clinical Trial Supplies, Powys, UK). CRF
animals were fed a diet containing 0.1% (w/w) adenine and vehicle or
the adenine diet supplemented with 2% (w/w) lanthanum carbonate.
Weekly food consumption was recorded for each animal. The aim was
to assess the effects of long-term treatment with lanthanum carbonate
on the mineral and bone abnormalities associated with CKD–MBD; this
was possible over 22 weeks of treatment.
Biochemical parameters
Blood samples were collected from the retro-orbital sinus under isoflurane
anaesthesia prior to the induction of CRF (Week −3) and after 0, 4, 8, 12
and 22 weeks of treatment. At the end of the study, rats were anaesthetized
with isoflurane for final blood collection. Animals were then sacrificed,
and tissues were carefully collected and preserved for measurement of
lanthanum content or histomorphometric analysis. Serum samples were
stored on ice before assessment of blood biochemistry.
Serum samples from all time points were assayed for creatinine, inor-
ganicphosphorus, totalcalcium,alkaline phosphatase,alanine aminotrans-
ferase, aspartate aminotransferase and CO2 using an Olympus AU400
Clinical Chemistry Analyzer (Olympus America Inc., Center Valley, PA,
USA). Ionizedcalcium was measured in wholebloodusinga BayerRapid-
lab 865 (Bayer, Pittsburgh, PA, USA). The serum samples collected before
sacrifice were immunoassayed for 25-hydroxyvitamin D (radioimmuno-
assay, DiaSorin Inc., Stillwater, MN, USA), 1,25-dihydroxyvitamin D
(radioimmunoassay, Nichols Institute Diagnostics, San Juan Capistrano,
CA, USA) and PTH (enzyme-linked immunosorbent assay, Immutopics
International, San Clemente, CA, USA). Whole blood pH was measured
using an electrochemical half-cell (Bayer Rapidlab 865).
Urine samples were collected at Week −3 and after 0, 4, 8, 12, 18 and
22 weeks of treatment. Animals were housed in metabolic cages for 18 h.
Thymol was added to preserve samples, and the volume and pH were
measured. Samples were then centrifuged (3000 rpm, 10 min, 4°C) before
being analysed for calcium and phosphorus using an Olympus AU400
Clinical Chemistry Analyzer. Only urine phosphorus was assessed at
Week 18 of treatment.
Tissue lanthanum analysis
Care was taken at autopsy to avoid cross-contamination of lanthanum be-
tween tissues because transfer of lanthanum present at high concentra-
tions in the gastrointestinal tract and on the skin could result in
misleading results [20]. Samples of soft tissue (250 mg) and bone
(60 mg) were immediately frozen for tissue lanthanum analysis. Samples
were analysed using previously validated methods [20] by inductively
coupled plasma–atomic emission spectrometry (ICP–AES; Spectro Cir-
os
TM CCD ICP-Atomic Emission Spectrometer, 408.672 nm line) or in-
ductively coupled plasma–mass spectrometry (ICP–MS; Agilent HP4500
ICP Mass Spectrometer), using praseodymium as an internal standard.
ICP–AES was used to quantify lanthanum in the range 0.01–10 μg/mL
and ICP–MS for tissues containing lanthanum in the range 0.021–
10 ng/mL, with accuracy and precision in the range 98.5–103.5%.
The lower limit of quantitation varied dependent on the weight of the
tissue samples: 1.5–13.7 ng/g wet weight for soft tissues and 33 ng/g
wet weight for bone.
Bone histomorphometry
Bone specimens for histomorphometric analysis were fixed in 10% buf-
fered formalin immediately after collection. The marrow cavity of the left
proximal tibia was exposed using a low-speed diamond wheel saw; the cut
was made in a frontal plane at an angle of 90° to the tibial tuberosity to
create a flat surface for positioning and embedding. A second cut was
made ~1.5 cm away from the proximal end, and the resulting section of
proximal tibia was processed for histology using polymethyl methacrylate
as an embedding medium. Following processing and embedding, tibial
samples were sectioned using a rotary microtome equipped with a tung-
sten carbide microtome knife. After blocks were trimmed and faced to the
sampling site, 5-μm sections were cut and stained with Goldner’st r i -
chrome for bright-field microscopy.
Following staining, bone histomorphometry was performed using an
OsteoMeasure software program (version 4.00c, OsteoMetrics, Inc., At-
lanta, GA, USA) interfaced with a Nikon Eclipse E400 light/epifluores-
cent microscope and video subsystem. Static histomorphometry of the
secondary spongiosa of the proximal tibia was performed in a 1.4-
mm × 2.1-mm area. The region of interest was determined by locating
the upper edge of the growth plate and scanning down by ~1.4 mm.
Osteoblast, osteoclast and osteoid parameters were measured using a
20× objective. All other parameters were measured with a 10× objective.
Fig. 3. Serum PTH levels in rats with normal renal function or chronic
renal failure after 22 weeks of treatment with vehicle or lanthanum
carbonate. *P < 0.05 vs all other groups. NRF, normal renal function;
CRF, chronic renal failure.
Table 1. Blood biochemistry in rats with normal renal function or chronic renal failure after 22 weeks of treatment with lanthanum carbonate or vehicle
Parameter
NRF + vehicle
(n = 10)
a
CRF + vehicle
(n =8 )
b
NRF + lanthanum carbonate
(n = 10)
c
CRF + lanthanum carbonate
(n =8 )
d
1,25-dihydroxyvitamin D (pg/mL) 437.20 ± 45.53 318.55 ± 59.67 333.97 ± 22.41 346.97 ± 44.23
25-hydroxyvitamin D (ng/mL) 21.53 ± 1.04 28.47 ± 2.43
a 22.66 ± 0.72 31.30 ± 3.89
a.c
Alkaline phosphatase (U/L) 51.10 ± 2.07 146.38 ± 8.54
a,c 56.30 ± 3.43 125.25 ± 44.28
a,c
Alanine aminotransferase (U/L) 31.40 ± 5.53 50.13 ± 5.61 39.60 ± 9.41 45.75 ± 16.18
Aspartate aminotransferase (U/L) 97.10 ± 10.13 107.13 ± 10.77 89.00 ± 5.43 95.88 ± 33.90
pH 7.42 ± 0.01 7.35 ± 0.03
a 7.39 ± 0.01 7.38 ± 0.02
Serum CO2 (mEq/L) 22.50 ± 0.34 21.71 ± 0.42 23.50 ± 0.37
b 22.25 ± 0.56
Data are presented as mean ± standard error of the mean. Superscript letters indicate a significant difference to corresponding group.
NRF, normal renal function; CRF, chronic renal failure.
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bone area, fibrosis tissue area, osteoblast and osteoid perimeters, osteoid
area, osteoid thickness, and osteoclast perimeter were measured. Bone
surface/volume, trabecular bone volume, woven bone volume, fibrosis tis-
sue volume, osteoid volume, osteoid surface, osteoblast surface and osteo-
clast surface were calculated according to standardized formulae defined
by Parfitt et al. [21].
Statistical analyses
All statistical analyses were conducted using SAS statistical software
(SAS Institute, Cary, NC, USA). Multiple group comparisons were con-
ducted using one-way (group) analysis of variance by either Duncan or
Dunnett's procedure using the vehicle-fed CRF group as reference. Data
collected at different time points in the study were analysed separately.
Results are reported as mean ± standard error of the mean (SEM), unless
otherwise stated.
Results
Body weight, food intake and survival
NRF animals continued to gain weight during the study;
addition of lanthanum carbonate to the diet did not affect
weekly food consumption but resulted in slight increases
in body weight gain (P < 0.05 at Week 14–15). Animals
receiving the 0.75% adenine-supplemented diet consumed
less food than their NRF counterparts and did not gain
weight during the 3-week disease-induction period. Mod-
erate body weight gain occurred after CRF animals were
switched to the 0.1% adenine maintenance diet; this gain
was unaffected by treatment with lanthanum carbonate.
After 18 weeks, adenine was removed from the mainten-
ance diet owing to observation of significant clinical signs
of illhealthinCRFrats.After22weeks,survivalofratswas
8/10 in both the vehicle-treated and lanthanum-carbonate-
treated CRF groups; all NRF rats survived. The study was
terminated at this point to ensure that there were sufficient
numbers of survivors for statistical analyses. Lanthanum
carbonate had no adverse effects on the behaviour of ani-
mals or on tissue histology. Examination of the CRF rats
that died during the study revealed that severe renal failure
was the cause of death.
Blood biochemistry
Blood biochemistry was assessed before induction of CRF
(Week −3), at the end of disease induction (Week 0) and
Fig. 4. Changes in (A) urinary phosphorus and (B) urinary calcium
excretion in rats with normal renal function or chronic renal failure
during 22 weeks of treatment with vehicle or lanthanum carbonate. A.
P < 0.05 NRF + lanthanum carbonate vs NRF + vehicle, Week 4–22.
P < 0.05 CRF + lanthanum carbonate vs CRF + vehicle, Week 4–22.
B. P < 0.05 CRF + lanthanum carbonate vs CRF + vehicle, Week 4–
12. Data are presented as mean ± standard error of the mean. NRF,
normal renal function; CRF, chronic renal failure. Dashed vertical line
indicates initiation of vehicle or lanthanum carbonate treatment.
Table 2. Tissue lanthanum concentrations in rats with normal renal function or chronic renal failure after 22 weeks of treatment with lanthanum
carbonate or vehicle
Tissue
Tissue lanthanum concentrations (ng/g)
NRF + vehicle
(n = 10)
a
CRF + vehicle
(n =8 )
b
NRF + lanthanum carbonate
(n = 10)
c
CRF + lanthanum carbonate
(n =8 )
d
Liver 1.8 (1.4, 2.5) 3.7 (2.0, 7.6)
a 244.6 (206.3, 372.1)
a,b 1964.5 (953.4, 2995.3)
a–c
Femur head 12.0 (9.9, 17.2) 14.6 (10.6, 18.8) 559.6 (408.6, 730.9)
a,b 1322.5 (1098.5, 2005.1)
a–c
Femur shaft 13.1 (8.2, 18.7) 17.2 (12.6, 21.0) 326.7 (243.3, 421.0)
a,b 927.7 (716.2, 1107.5)
a–c
Skeletal muscle 2.0 (1.7, 23.5) 5.0 (1.1, 64.5) 57.5 (15.5, 115.9)
a,b 137.4 (17.9, 256.2)
a,b
Kidney 1.9 (1.5, 4.5) 1.7 (1.0, 12.0) 215.5 (156.5, 241.4)
a,b 109.9 (88.4, 246.6)
a,b
Heart 2.1 (1.6, 6.2) 5.0 (1.0, 12.3) 11.6 (8.1, 52.2)
a,b 40.3 (16.9, 82.3)
a,b
Brain (cerebellum) 2.1 (1.3, 5.2) 1.6 (0.8, 4.7) 15.2 (5.0, 40.0)
a,b 12.4 (4.6, 62.16)
a,b
Brain (cerebrum) 2.1 (1.6, 3.2) 1.3 (0.8, 3.1) 9.5 (3.0, 47.6)
a,b 8.2 (3.4, 23.22)
a,b
Brain (mid) 1.5 (0.9, 2.3) 1.2 (0.5, 2.2) 9.9 (2.7, 26.9)
a,b 8.0 (3.4, 28.61)
a,b
Data are presented as median wet weight (10–90th percentiles). Superscript letters indicate a significant difference to corresponding group.
NRF, normal renal function; CRF, chronic renal failure.
1806 S. Damment et al.during the subsequent 22 weeks of treatment. At the end of
diseaseinduction, serum creatininewas significantlyhigher
in CRF rats than in NRF animals (P < 0.05). During the
subsequent 22 weeks of treatment, serum creatinine re-
mained elevated in CRF rats, but levels were lower in those
treated with lanthanum carbonate than in vehicle-treated
controls (P < 0.05 for creatinine at Week 22, Figure 1).
The addition of lanthanum carbonate to the diet of NRF
animals did not affect creatinine levels.
Serum phosphorus, ionized calcium and calcium ×
phosphorus product (Ca × P) decreased slightly over time
in NRF rats (Figure 2); lanthanum carbonate treatment did
Fig. 5. Histomorphometry of trabecular bone from rats with normal renal function or chronic renal failure after 22 weeks of treatment with vehicle or
lanthanum carbonate. *P < 0.05 vs all other groups,
†P < 0.05 vs NRF + LC,
‡P < 0.05 vs NRF groups. Data are presented as mean ± standard error of
the mean. CRF, chronic renal failure; LC, lanthanum carbonate; NRF, normal renal function; Veh, vehicle. (A) Trabecular bone volume (%) =
[trabecular bone area (mm
2)/total tissue area (mm
2)] × 100. (B) Osteoid thickness (μm). (C) Osteoid volume (%) = [osteoid area (mm
2)/trabecular
bone area (mm
2)] × 100. (D) Osteoid surface (%) = [osteoid perimeter (mm)/trabecular bone perimeter (mm)] × 100. (E) Osteoblast surface (%) =
[osteoblast perimeter (mm)/trabecular bone perimeter (mm)] × 100. (F) Osteoclast surface (%) = [osteoclast perimeter (mm)/trabecular bone perimeter
(mm)] × 100. (G) Woven bone volume = [woven bone area (mm
2)/total tissue area (mm
2)] × 100. (H) Fibrosis tissue volume = [fibrosis tissue area
(mm
2)/total tissue area (mm
2)] × 100.
Lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure 18071808 S. Damment et al.not significantly influence levels of these parameters. The
induction of CRF resulted in significant increases in serum
phosphorus and Ca × P, and a decrease in ionized calcium
compared with NRF animals. When CRF rats were
switched to the 0.1% adenine maintenance diet, levels im-
proved slightly but remained abnormal. Treatment with
lanthanum carbonate significantly reduced serum phos-
phorus (by ~50% vs vehicle) and increased ionized cal-
cium such that at some time points, levels were not
significantly different from those observed in NRF rats.
Ca × P was also significantly reduced in CRF rats treated
with lanthanum carbonate, compared with vehicle-treated
controls (P < 0.05).
Levels of PTH (Figure 3) and vitamin D metabolites
(Table 1) were assessed at the end of treatment; PTH levels
were significantly higher in vehicle-treated CRF animals
than in their NRF counterparts (mean 24-fold higher,
P < 0.05). Treatment with lanthanum carbonate inhibited
the increase in PTH levels: at the end of the study, mean
PTH values in CRF rats treated with lanthanum carbonate
were only 3-fold higher than in the NRF groups treated
with lanthanum carbonate or vehicle, and the differences
between these groups were not statistically significant.
CRF rats had higher levels of 25-hydroxyvitamin D than
NRF animals; lanthanum carbonate treatment did not sig-
nificantly alter levels in CRF or NRF treatment groups.
There were no statistically significant differences in
1,25-dihydroxyvitamin D levels between any treatment
groups. After 22 weeks of treatment, there were no effects
of lanthanum carbonate on the plasma levels of alkaline
phosphatase, alanine aminotransferase or aspartate amino-
transferase in CRF or NRF rats (Table 1).
Whole blood pH and serum CO2 were measured at vari-
ous time points to assess the acidic milieu associated with
CRF, and any effects of lanthanum carbonate treatment.
Three weeks after initiation, adenine supplementation
(0.75%) induced significant reductions in serum CO2
and whole blood pH suggesting acidosis in CRF rats. Eight
weeks after the switch to the maintenance diet (0.1% ad-
enine), serum CO2 had returned to normal. Treatment of
CRF rats with lanthanum carbonate resulted in consistently
higher whole blood pH (not significant), but not serum
CO2, when compared with vehicle-treated CRF animals
(Table 1).
Urine biochemistry
Lanthanum carbonate treatment resulted in a decrease in
urinary phosphorus excretion and an increase in urinary
calcium excretion compared with vehicle-treated controls
(Figure 4). Indeed, in CRF rats, treatment with lanthanum
carbonate reduced urinary phosphorus excretion by ~40%
compared with vehicle-treated animals (P < 0.05); this re-
duction was maintained throughout the study.
Tissue lanthanum concentrations
The distribution of lanthanum in various tissues is shown
in Table 2. As expected, lanthanum carbonate treatment
was associated with the detection of lanthanum in the tis-
sues of NRF and CRF animals. CRF was associated with
increased deposition of lanthanum in liver and bone
(P < 0.05 vs NRF), but not in the other organs examined.
Bone histomorphometry
Undecalcified histology preparation of the metaphysis of
the proximal tibia was performed, and samples were ana-
lysed for abnormalities. The parameters described in the
Materials and methods section were quantified (Figure 5).
There were no statistically significant differences between
vehicle and lanthanum carbonate treatment groups in the
NRF rats. Vehicle-treated CRF rats had significantly in-
creased trabecular bone volume, osteoid thickness, osteo-
blast surface, woven bone volume and fibrosis tissue
volume compared with NRFanimals (P < 0.05). Trabecular
bone volume, osteoid thickness, woven bone volume
and fibrosis tissue volume were significantly lower in
lanthanum-carbonate-treated CRF animals, compared
with vehicle-treated controls (P < 0.05). Despite lan-
thanum carbonate treatment, osteoid surface and volume,
and osteoblast and osteoclast surfaces remained elevated.
Representative images are shown in Figure 6.
Discussion
Maintenance of phosphorus balance is essential to limit the
progression of CKD–MBD including secondary hyper-
parathyroidism, renal bone disease and vascular calcifica-
tion [22]. In this study, using the adenine-induced CRF rat
model, long-term treatment with lanthanum carbonate was
shown to suppress hyperphosphataemia and secondary
hyperparathyroidism with subsequent beneficial effects
on bone disease.
Several animal models of CRF have been used to inves-
tigate the efficacy of pharmacological agents on para-
meters associated with CKD–MBD. One such model
uses dietary administration of 0.75% adenine to induce
CRF. In this model, animals exhibit severe secondary
hyperparathyroidism and bone abnormalities, which occur
in weeks. Tamagaki et al. [16] recently described the
pathology associated with adenine-induced CRF in rats, in-
cluding secondary hyperparathyroidism and bone disease.
Fig. 6. Representative images of the proximal tibia of rats with normal renal function or chronic renal failure after 22 weeks of treatment with vehicle or
lanthanum carbonate. Sections (5 μm) were cut and stained with Goldner's trichrome for bright-field microscopy. Representative images (low and high
magnification) from each treatment group are presented. (A) NRF + vehicle (low magnification). (B) NRF + lanthanum carbonate (low magnification).
(C) CRF + vehicle (low magnification). (D) CRF + lanthanum carbonate (low magnification). (E) NRF + vehicle (high magnification). (F) NRF +
lanthanum carbonate (high magnification). (G) CRF + vehicle (high magnification). (H) CRF + lanthanum carbonate (high magnification). CRF +
vehicle animals displayed significantly increased trabecular bone volume in the metaphysis of the proximal tibia. At high magnification, increased
osteoid and fibrosis tissues were evident in CRF + vehicle (G) but not in CRF + lanthanum carbonate (H) animals. NRF, normal renal function; CRF,
chronic renal failure.
Lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure 1809They reported that supplementation of the diet with 0.75%
adenine for up to 6 weeks resulted in abnormalities, in-
cluding elevation of serum creatinine and phosphorus,
and a decrease in serum calcium. These changes were as-
sociated with markedly enlarged parathyroid glands, ele-
vated PTH levels and increased levels of fibrosis in bone
tissue. Comparable changes in serum parameters were also
described by Nagano et al. [17], using a similar model
whereby animals received 4 weeks of adenine treatment
(2 weeks at 0.75% and 2 weeks at 0.5%) followed by
8 weeks on a normal diet.
This model has been used to examine the effects of a
phosphate binder, sevelamer hydrochloride, on renal bone
disease parameters over a period of 5 weeks [18]. It was
demonstrated that sevelamer hydrochloride treatment sup-
pressed abnormalities in serum phosphorus, calcium and
PTH, resulting in normalization of parameters associated
with bone disease. Following demonstration of these posi-
tive effects of a phosphate binder on bone pathology, we
modified the adenine model to investigate the effects of
long-term treatment with lanthanum carbonate on abnor-
mal parameters of CKD–MBD and bone pathology.
In our model, dietary supplementation with 0.75%
adenine resulted in CRF, including elevation of serum
creatinine and phosphorus, and a decrease in ionized cal-
cium. Following the reduction of dietary adenine to 0.1%,
creatinine levels stabilized, indicating no further reduction
ofrenalfunction.Asaresult,serumphosphorusandionized
calcium also remained more stable. However, PTH levels
were extremely high (mean >20 000 pg/mL) following
18 weeks of adenine treatment. In contrast, PTH levels
observed in NRF control animals were ~900 pg/mL,
w h i c hw e r eh i g h e rt h a nr e p o r t e db yT a m a g a k iet al.
and Nagano et al. (both ~100 pg/mL) [16,17]. This vari-
ation in PTH data could not be attributed to different
methods of PTH measurement because all investigators
used similar assays. However, it could be due to the lower
concentration of calcium (0.8%) in the diet of our ani-
mals, compared with those used in the earlier studies
(1.2% and 1.17%, respectively [16,17]). While the values
observed were different, the fold increases in PTH asso-
ciated with adenine treatment were of similar magnitude
across these studies. In the study by Nagano et al. [17],
4 weeks of adenine treatment (2 weeks at 0.75% and
2 weeks at 0.5%) followed by 8 weeks on a normal diet
resulted in an increase in PTH from ~120 pg/mL at base-
line to ~6000 pg/mL at the end of the 12-week study (a
50-fold increase). In the study by Tamagaki et al. [16],
supplementation of the diet with 0.75% adenine for
6 weeks resulted in PTH levels of 1812 pg/mL, compared
with 96 pg/mL in normal controls (a 19-fold increase). In
our study, administration of adenine for 18 weeks could
have resulted in severe parathyroid gland hyperplasia
and secondary hyperparathyroidism (represented by a
24-fold increase in PTH levels), driven by conditions of
hyperphosphataemia and hypocalcaemia.
In this study, 1,25-dihydroxyvitamin D levels were not
significantly different between NRF and CRF groups after
22 weeks of treatment. This was somewhat surprising
given that 1,25-dihydroxyvitamin D deficiency is widely
accepted as an important factor contributing to the devel-
opment of secondary hyperparathyroidism in renal failure
[23,24]. The finding is consistent with observations in
5/6thnephrectomizedmaleWistarratsat14weeksaftersur-
gery[25].Incontrast,Tamagakietal.[16]andNaganoetal.
[17] reported significant decreases in 1,25-dihydroxyvita-
min D after 4–6 weeks of adenine treatment. In rats with
moderate renal failure, 1,25-dihydroxyvitamin D produc-
tion is maintained as PTH levels increase and/or a rise in
serum phosphorus levels is prevented [23,26]; reduction
of 1,25-dihydroxyvitamin D levels occurs when renal func-
tion is markedly decreased. Differences in the phosphorus,
calcium and vitamin D3 content of the diet may partly ac-
count for the contrasting observations seen in these studies,
but further investigation of fibroblast growth factor-23 le-
vels (unfortunately not possible in this study) could help
to elucidate the reason for the lack of differences in 1,25-di-
hydroxyvitamin D levels observed across the treatment
groups in the present study.
Bone histomorphometry revealed a severe form of bone
disease in CRF rats, as indicated by significant increases in
trabecular bone volume, osteoblast surface, woven bone
volume and fibrosis tissue volume. This is likely to have
resulted from the severe and prolonged secondary hyper-
parathyroidism, with excessive production of woven bone
responsible for large increases in trabecular bone volume,
and explains the osteosclerotic appearance of the trabecu-
lar bone in the CRF rats. Similar observations have been
made by other investigators [16]. Linear regression ana-
lyses (data not shown) demonstrated that the degree of fi-
brosis significantly correlated with PTH levels, but it was
interesting to see that fibrosis correlated to an even greater
extent with serum phosphorus levels. The metabolic acid-
osis evident in CRF rats would also contribute to the sever-
ity of the bone disease observed, possibly by directly
inducing dissolution of bone, and by effects on osteoblast
and osteoclast function.
The bone histology observed is consistent with that re-
ported by Miller et al. [27], who demonstrated increased
trabecular bone volume, osteoblast number and osteoclast
number in 5/6th nephrectomized rats with severe second-
ary hyperparathyroidism, and with that reported by Tama-
gaki et al. [16], who found increased fibrosis and bone
volume in adenine-treated animals. Katsumata et al. [18]
also observed significant increases in fibrosis volume, por-
osity ratio and osteoid volume in their adenine-induced
model.
In this study, the phosphate-binding effectiveness of
lanthanum carbonate was demonstrated by reductions in
urinary phosphorus excretion and serum phosphorus levels,
compared with vehicle treatment. Treatment with lan-
thanum carbonate prevented CRF-induced hyperphospha-
taemia, such that levels of serum phosphorus were similar
to those in NRF rats. Normalization of serum phosphorus
suppressed the increase in PTH levels observed in ve-
hicle-treated CRF animals, such that levels observed in
lanthanum-carbonate-treated rats were not significantly
different to those observed in NRF rats. These data are
consistent with those reported by Ben-Dov et al. [28],
using a less severe adenine-induced model of CRF (0.3%
adenine). These investigators treated the animals with 3%
elemental lanthanum, which resulted in significant reduc-
1810 S. Damment et al.tion in PTH to levels similar to those observed in control
animals. They have also recently demonstrated that lan-
thanum carbonate, through correction of serum phos-
phorus levels, destabilizes PTH messenger RNA, thereby
decreasing PTH expression [29].
Lanthanum carbonate treatment was associated with an
increase in ionized calcium to levels similar to those ob-
served in NRF animals, despite an increase in urinary cal-
cium excretion. As postulated for sevelamer hydrochloride
[17], the increase in ionized calcium is likely to have been
due, at least in part to a counter-ion effect of reducing
serum phosphorus, and could also be due to increased ab-
sorption of free calcium made available by the alternative
binding of phosphate to lanthanum in the gastrointestinal
tract. PTH-regulated mechanisms for renal mineral hand-
ling are partially preserved in CRF rats [30]. Therefore,
the increase in urinary calcium excretion is likely to be a
homeostatic response driven by the reduction of PTH le-
vels associated with lanthanum carbonate treatment. This
effect has also been noted previously with sevelamer
hydrochloride [30]. Lanthanum carbonate treatment did
not affect serum levels of vitamin D metabolites in either
NRF or CRF rats, but showed a trend towards correction of
CRF-induced acidosis. This is in contrast to reports about
sevelamer hydrochloride, which has been shown to exacer-
bate acidosis in clinical studies [31,32].
Treatment with lanthanum carbonate limited the pro-
gression of severe CRF-induced bone disease, particularly
fibrosis. Given the significant correlation between levels
of fibrosis and serum phosphorus, this was not surprising.
The key evidence supporting this finding was lower levels
oftrabecular bonevolume,wovenbonevolumeandfibrosis
volume compared with levels observed in vehicle-treated
CRF rats. Partial correction of acidosis by lanthanum car-
bonate may also have had beneficial effects on bone para-
meters. Differences in osteoid parameters, osteoblast
surface and osteoclast surface were not as profound, pos-
sibly because PTH levels were still elevated in some of the
lanthanum-carbonate-treated rats. It is likely that control of
the parameters of CKD–MBD reduced the synthesis of
woven bone and fibrosis.
A limitation of this study is that animals were not treated
with tetracycline to label bone. As the adenine-induced
model results in high-turnover bone disease, at the time of
study design, it was not thought necessary to differentiate
between high and low bone turnover, as would be permitted
by tetracycline labelling. Therefore, analysis of bone
mineralization and turnover was not possible, preventing
presentation of the data according to the Kidney Disease:
Improving Global Outcomes Turnover, Mineralization and
Volume (TMV) classification system. Therewere no effects
of treatment on mortality; however, the study was not
designed with mortality as an end point.
In this study, CRF was associated with increased depos-
ition of lanthanum in the bone and liver, but not in the
other organs examined. Deposition of lanthanum in the
bone was 2–3-fold higher in CRF rats than in NRF con-
trols. The levels (~1500 ng/g) were consistent with previ-
ous animal and human studies [33,34]. Also consistent
with the results of previous studies [25,34–36], there was
no evidence of adverse effects of lanthanum carbonate on
bone. In the liver of CRF rats, lanthanum concentrations
remained <2000 ng/g wet weight, consistent with the
results of previous studies in which levels exceeding
3000 ng/g have never been observed, irrespective of dose
or treatment duration [28,37–39]. Therewas no histological
evidence of adverse effects of lanthanum on the liver, and
there was no difference in the levels of liver function
enzymes between groups treated with lanthanum carbon-
ate or vehicle. The presence of lanthanum in the liver is
consistent with biliary excretion being the main route of
elimination [40].
This study demonstrates that long-term treatment with
lanthanum carbonate to control hyperphosphataemia can
reduce the abnormalities of mineral and bone metabolism
associated with CRF in rats. Furthermore, this study de-
monstrates that the modified adenine-induced model may
be a useful tool to examine the complex interplay be-
tween mineral metabolism and its subsequent effects on
bone.
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